Division of Hematology-Oncology, The Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY 10029, USA.
Am J Hematol. 2012 Sep;87(9):931-3. doi: 10.1002/ajh.23260. Epub 2012 Jun 22.
Umbilical cord-blood transplantation is considered an effective treatment strategy for acute lymphoblastic leukemia (ALL) when a human leukocyte antigen (HLA)-matched donor is unavailable. The use of a second unit helps ensure engraftment in larger adults and those with comorbidities, even though only one unit engrafts in most patients. Herein, we present the clinical and laboratory characteristics of a patient who developed donor-derived myelodysplastic syndrome (ddMDS) after double umbilical cord-blood transplantation (dUCB HSCT). To our knowledge, no cases of ddMDS have been described in a patient with a history of ALL in molecular remission after receiving a dUCB HSCT. Current molecular techniques, including analysis of short tandem repeats (STR) and fluorescence in situ hybridization (FISH) allowed us to firmly establish donor origin.
当无法获得人类白细胞抗原 (HLA) 匹配的供体时，脐带血移植被认为是治疗急性淋巴细胞白血病 (ALL) 的有效治疗策略。即使大多数患者只植入一个单位，使用第二个单位也有助于确保在较大的成年人和合并症患者中植入。在此，我们介绍了一名患者的临床和实验室特征，该患者在接受双脐带血移植 (dUCB HSCT) 后发生供体衍生骨髓增生异常综合征 (ddMDS)。据我们所知，在接受 dUCB HSCT 后处于分子缓解的 ALL 病史患者中，尚无 ddMDS 的病例描述。目前的分子技术，包括短串联重复序列 (STR) 和荧光原位杂交 (FISH) 的分析，使我们能够确定供体的来源。
